The American Journal of Managed Care

ELIXA Trial Results Find No Cardiac Risk, Benefit for Lixisenatide

Results are the first from a cardiovascular safety trial in the GLP-1 agonist class. A commentator at the 75th Scientific Sessions of the American Diabetes Association asked whether the FDA-mandated ...
Medscape

No CV Benefit With Lixisenatide in ELIXA, but Results Reassure

BOSTON (updated June 9) — Lixisenatide (Lyxumia, Sanofi), an injectable glucagonlike peptide (GLP-1) agonist used for the treatment of type 2 diabetes, did not show a benefit on cardiovascular ...
The American Journal of Managed Care

ELIXA Results on Lixisenatide Published in NEJM

Results first presented at the American Diabetes Association in June are published. The new drug application has since been filed at FDA. Results from the ELIXA trial, which showed that the GLP-1 ...
TCTMD

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Popular Glucose-Lowering Drugs Also Show No Risk of Hypoglycemia or Pancreatic Injury, and Modest Benefit for Weight Compared to Placebo BOSTON, One member of a widely prescribed class of drugs used ...
FiercePharma

ELIXA Trial Shows CV Safety of Lixisenatide

In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, ...
Healio

ELIXA: Lixisenatide slows, reduces macroalbuminuria risk in type 2 diabetes with CVD

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults with type 2 diabetes, established cardiovascular ...
FierceBiotech

Sanofi Provides Update on Lixisenatide New Drug Application in U.S.

Paris, France - September 12, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today its decision to withdraw the lixisenatide New Drug Application (NDA) in the U.S., which included early interim ...